Published in World J Gastroenterol on November 07, 2010
Non invasive tools for the diagnosis of liver cirrhosis. World J Gastroenterol (2014) 1.00
Alcohol Consumption, Progression of Disease and Other Comorbidities, and Responses to Antiretroviral Medication in People Living with HIV. AIDS Res Treat (2012) 0.94
Abnormal liver stiffness assessed using transient elastography (Fibroscan®) in HIV-infected patients without HBV/HCV coinfection receiving combined antiretroviral treatment. PLoS One (2013) 0.81
Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study. Medicine (Baltimore) (2016) 0.77
Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med (1998) 46.95
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (2006) 10.18
Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol (2003) 9.19
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS (1998) 8.88
Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol (1986) 6.20
Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology (2005) 5.93
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology (1999) 5.55
Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis (2001) 4.72
Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis (2008) 2.72
Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS (2001) 2.54
HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology (2005) 2.42
Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology (2007) 2.39
Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol (2005) 2.27
Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology (2009) 2.18
Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis (2003) 2.11
Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis (2003) 1.93
The role of laparoscopy in the diagnosis of cirrhosis. Gastrointest Endosc (1996) 1.89
Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr (2006) 1.87
Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS (2005) 1.52
Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut (2003) 1.48
Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut (2005) 1.28
Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. J Viral Hepat (2008) 1.20
Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. J Viral Hepat (2008) 1.11
Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Drug Saf (2005) 1.07
Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. J Viral Hepat (2011) 1.00
Impact of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. World J Gastroenterol (2009) 0.94
Percutaneous liver biopsy: a safe outpatient procedure? Digestion (2001) 0.92
Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology (2008) 0.92
Regression of liver fibrosis in hepatitis C virus/HIV-co-infected patients after treatment with pegylated interferon plus ribavirin. AIDS (2006) 0.92
Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients. Aliment Pharmacol Ther (2009) 0.90
Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies. Antivir Ther (2004) 0.87
Cryptogenic liver disease in HIV-seropositive men. HIV Med (2009) 0.85
Identification of liver fibrosis in HIV/HCV-coinfected patients using a simple predictive model based on routine laboratory data. J Viral Hepat (2007) 0.84
Non-celiac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: exploring a new clinical entity. Am J Gastroenterol (2012) 6.36
Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection. Eur J Immunol (2010) 3.71
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget (2011) 3.43
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) (2011) 2.72
Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology (2008) 2.28
TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology (2008) 2.25
PAP/HIP protein is an obesogenic factor. J Cell Physiol (2014) 1.98
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget (2012) 1.96
Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. Gut (2011) 1.87
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget (2012) 1.85
An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl (2007) 1.83
Successful treatment of small-for-size syndrome in adult-to-adult living-related liver transplantation: single center series. Clin Transplant (2007) 1.70
Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis. Radiology (2012) 1.65
GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget (2014) 1.56
Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res (2003) 1.55
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget (2012) 1.55
Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem (2003) 1.50
Hepatocellular carcinoma: comparison of two different periods at the same center. Eur J Intern Med (2010) 1.41
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol (2011) 1.40
Celiac disease in the developing countries: a new and challenging public health problem. World J Gastroenterol (2007) 1.40
Analysis of Mycobacterium tuberculosis-specific CD8 T-cells in patients with active tuberculosis and in individuals with latent infection. PLoS One (2009) 1.33
Cyclooxygenases in hepatocellular carcinoma. World J Gastroenterol (2006) 1.31
Heterogeneity and temporal dynamics of evolution of G1 human rotaviruses in a settled population. J Virol (2006) 1.25
Comparison of anti-transglutaminase ELISAs and an anti-endomysial antibody assay in the diagnosis of celiac disease: a prospective study. Clin Chem (2002) 1.24
Polymerase chain reaction in the diagnosis and prognosis of Mediterranean visceral leishmaniasis in immunocompetent children. Pediatrics (2002) 1.17
Emerging MEK inhibitors. Expert Opin Emerg Drugs (2010) 1.16
Expression of WISPs and of their novel alternative variants in human hepatocellular carcinoma cells. Ann N Y Acad Sci (2004) 1.09
Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways. J Hepatol (2011) 1.08
Liver biopsy findings from healthy potential living liver donors: reasons for disqualification, silent diseases and correlation with liver injury tests. J Hepatol (2008) 1.08
Can the serological status of anti-HBc alone be considered a sentinel marker for detection of occult HBV infection? J Med Virol (2008) 1.08
Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol (2006) 1.07
Efficacy of transcatheter embolization/chemoembolization (TAE/TACE) for the treatment of single hepatocellular carcinoma. World J Gastroenterol (2007) 1.07
Unusual assortment of segments in 2 rare human rotavirus genomes. Emerg Infect Dis (2010) 1.07
Selective depression of interferon-gamma and granulysin production with increase of proliferative response by Vgamma9/Vdelta2 T cells in children with tuberculosis. J Infect Dis (2002) 1.07
Advances in targeting signal transduction pathways. Oncotarget (2012) 1.06
Elevated blood Hsp60, its structural similarities and cross-reactivity with thyroid molecules, and its presence on the plasma membrane of oncocytes point to the chaperonin as an immunopathogenic factor in Hashimoto's thyroiditis. Cell Stress Chaperones (2013) 1.05
Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. J Hepatol (2005) 1.04
Louseborne Relapsing Fever in Young Migrants, Sicily, Italy, July-September 2015. Emerg Infect Dis (2016) 1.04
Molecular mechanisms of sorafenib action in liver cancer cells. Cell Cycle (2012) 1.01
Surveillance of multidrug-resistant gram-negative bacilli in a neonatal intensive care unit: prominent role of cross transmission. Am J Infect Control (2007) 1.01
Fecal assays detect hypersensitivity to cow's milk protein and gluten in adults with irritable bowel syndrome. Clin Gastroenterol Hepatol (2011) 1.00
Clarithromycin versus azithromycin in the treatment of Mediterranean spotted fever in children: a randomized controlled trial. Clin Infect Dis (2001) 1.00
Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovasc Diabetol (2014) 1.00
Correlation between expression of cyclooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma: possible role in tumor promotion and angiogenesis. World J Gastroenterol (2005) 1.00
Efficient human fetal liver cell isolation protocol based on vascular perfusion for liver cell-based therapy and case report on cell transplantation. Liver Transpl (2012) 1.00
Serum low density lipoprotein subclasses in asthma. Respir Med (2013) 1.00
Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors. Ann N Y Acad Sci (2004) 0.99
Induction of apoptosis by the proteasome inhibitor MG132 in human HCC cells: Possible correlation with specific caspase-dependent cleavage of beta-catenin and inhibition of beta-catenin-mediated transactivation. Int J Mol Med (2004) 0.99
Contribution of transjugular liver biopsy in patients with the clinical presentation of acute liver failure. Cardiovasc Intervent Radiol (2006) 0.98
Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinoma. World J Gastroenterol (2013) 0.96
Autoimmune enteropathy and colitis in an adult patient. Dig Dis Sci (2003) 0.96
Visceral leishmaniasis: host-parasite interactions and clinical presentation in the immunocompetent and in the immunocompromised host. Int J Infect Dis (2013) 0.95
Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells. Cell Cycle (2010) 0.95
Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients (2013) 0.94
Emerging Raf inhibitors. Expert Opin Emerg Drugs (2009) 0.94
Decreased serum granulysin levels in childhood tuberculosis which reverse after therapy. Tuberculosis (Edinb) (2007) 0.93
Solitary necrotic nodule of the liver: different pathological findings express a different histogenesis. Case Rep Gastroenterol (2008) 0.93
Detection of the norovirus variants GGII.4 hunter and GGIIb/hilversum in Italian children with gastroenteritis. J Med Virol (2006) 0.93
Cryptic Leishmania infantum infection in Italian HIV infected patients. BMC Infect Dis (2009) 0.93
Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway. Cancer Biol Ther (2007) 0.92
Canine-origin G3P[3] rotavirus strain in child with acute gastroenteritis. Emerg Infect Dis (2007) 0.92
Expression of wild-type and variant estrogen receptor alpha in liver carcinogenesis and tumor progression. OMICS (2011) 0.91
Androgen metabolism and biotransformation in nontumoral and malignant human liver tissues and cells. J Steroid Biochem Mol Biol (2009) 0.90
Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma: an immunohistochemical study . Ann N Y Acad Sci (2009) 0.89
IL-6 -174G/C polymorphism and IL-6 serum levels in patients with liver cirrhosis and hepatocellular carcinoma. OMICS (2011) 0.89
The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism. Cancer Lett (2012) 0.89
Long-lasting remission of primary hepatic lymphoma and hepatitis C virus infection achieved by the alpha-interferon treatment. Hematol J (2004) 0.89
Unusual MRI findings in an immunocompetent patient with EBV encephalitis: a case report. BMC Med Imaging (2011) 0.88
The health of irregular and illegal immigrants: analysis of day-hospital admissions in a department of migration medicine. Intern Emerg Med (2011) 0.88
Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth. Ann N Y Acad Sci (2009) 0.88
Five-year retrospective Italian multicenter study of visceral leishmaniasis treatment. Antimicrob Agents Chemother (2013) 0.86
Local estrogen formation by nontumoral, cirrhotic, and malignant human liver tissues and cells. Cancer Res (2003) 0.86
Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism. Mol Pharmacol (2009) 0.86
Prospective evaluation of hepatic steatosis in HIV-infected patients with or without hepatitis C virus co-infection. Int J Infect Dis (2012) 0.85
Genotyping of GII.4 and GIIb norovirus RT-PCR amplicons by RFLP analysis. J Virol Methods (2007) 0.85
Significance of autologous interleukin-6 production in the HA22T/VGH cell model of hepatocellular carcinoma. Ann N Y Acad Sci (2006) 0.85
Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients. Int J Mol Med (2011) 0.85
Altered androgen metabolism eventually leads hepatocellular carcinoma to an impaired hormone responsiveness. Mol Cell Endocrinol (2002) 0.85
Cystic echinococcosis of the liver and lung treated by radiofrequency thermal ablation: an ex-vivo pilot experimental study in animal models. World J Gastroenterol (2009) 0.85
Right hepatic lobe living donation: a 12 years single Italian center experience. World J Gastroenterol (2013) 0.85
Impact of blood transfusion on early outcome of liver resection for colorectal hepatic metastases. J Surg Oncol (2010) 0.84
Dairy calcium intake and lifestyle risk factors for bone loss in hiv-infected and uninfected Mediterranean subjects. BMC Infect Dis (2012) 0.84